In vivo delivery and long-term tissue retention of nanoencapsulated sirolimus using a novel porous balloon angioplasty system

EuroIntervention

Volumn 12, Issue 6, 2016, Pages 740-747

  Granada, Juan F ^a   Tellez, Armando ^a,b   Baumbach, William R ^c   Bingham, Brendan ^c   Keng, Yen Fang ^c   Wessler, Jeffrey ^d   Conditt, Gerard ^a   McGregor, Jennifer ^a   Stone, Gregg ^d   Kaluza, Greg L ^a   Leon, Martin B ^d  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b Alizee Pathology   (United States)

^c Caliber Therapeutics   (United States)

^d Columbia University Medical College ^*  (United States)

Author keywords

Drug eluting balloon; Extended release; Pharmacokinetics; Porcine coronary artery model; Porous angioplasty balloon; Sirolimus nanoparticle

Indexed keywords

NANOPARTICLE; RAPAMYCIN; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RETENTION; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; IN-STENT RESTENOSIS; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PIG; SIROLIMUS ELUTING CORONARY STENT; ANIMAL; CORONARY BLOOD VESSEL; CORONARY RESTENOSIS; DEVICES; DRUG EFFECTS; EVALUATION STUDY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CORONARY RESTENOSIS; CORONARY VESSELS; FEMALE; MALE; NANOPARTICLES; SIROLIMUS; SWINE;

EID: 84983044365     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY15M10_01     Document Type: Article

References (21)

1. Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation. 2010;121:2672-80.
2. Loh JP, Barbash IM, Waksman R. The current status of drugcoated balloons in percutaneous coronary and peripheral interventions. EuroIntervention. 2013;9:979-88.
3. Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11:13-23.
4. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006; 355:2113-24.
5. Habara S, Kadota K, Kanazawa T, Ichinohe T, Kubo S, Hyodo Y, Otsuru S, Hasegawa D, Tada T, Tanaka H, Fuku Y, Goto T, Mitsudo K. Paclitaxel-coated balloon catheter compared with drugeluting stent for drug-eluting stent restenosis in routine clinical practice. EuroIntervention. 2015 Feb 19. [Epub ahead of print].
6. Levin A, Vukmirovic N, Hwang C, Edelman E. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A. 2004;101: 9463-7.
7. Kolachalama VB, Pacetti SD, Franses JW, Stankus JJ, Zhao HQ, Shazly T, Nikanorov A, Schwartz LB, Tzafriri AR, Edelman ER. Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy. Circulation. 2013;127:2047-55.
8. Buerke M, Guckenbiehl M, Schwertz H, Buerke U, Hilker M, Platsch H, Richert J, Bomm S, Zimmerman GA, Lindemann S, Mueller-Werdan U, Werdan K, Darius H, Weyrich AS. Intramural delivery of Sirolimus prevents vascular remodeling following balloon injury. Biochim Biophys Acta. 2007;1774:5-15.
9. Cremers B, Toner JL, Schwartz LB, von Oepen R, Speck U, Kaufels N, Clever YP, Mahnkopf D, Bohm M, Scheller B. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. Clin Res Cardiol. 2012;101:469-76.
10. Granada JF, Milewski K, Zhao H, Stankus JJ, Tellez A, Aboodi MS, Kaluza GL, Kreuger CG, Virmani R, Schwartz LB, Nikanorov A. Vascular response to zotarolimus-coated balloons in injured superficial femoral arteries of the familial hypercholesterolemic Swine. Circ Cardiovasc Interv. 2011;4:447-55.
11. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-93.
12. Lemos PA, Farooq V, Takimura CK, Gutierrez PS, Virmani R, Kolodgie F, Christians U, Kharlamov A, Doshi M, Sojitra P, van Beusekom HM, Serruys PW. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013;9:148-56.
13. Luderer F, Löbler M, Rohm HW, Gocke C, Kunna K, Köck K, Kroemer HK, Weitschies W, Schmitz KP, Sternberg K. Biodegradable sirolimus-loaded poly(lactide) nanoparticles as drug delivery system for the prevention of in-stent restenosis in coronary stent application. J Biomater Appl. 2011;25:851-75.
14. Verdouw PD, Wolffenbuttel BH, van der Giessen WJ. Domestic pigs in the study of myocardial ischemia. Eur Heart J. 1983;4 Suppl C:61-7.
15. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-74.
16. CYPHER Instructions for Use. Cordis Corporation, Miami, FL 33102-5700, 2003. http://www. accessdata. fda. gov/cdrh-docs/pdf2/P020026c. pdf
17. Abbott Vascular XIENCE V Everolimus Eluting Coronary Stent System; PMA P070015 Panel Package; U. S. Food and Drug Administration, 2007. http://www. fda. gov/ohrms/dockets/ac/07/briefing/2007-4333b1-02-Panel-Exec%20Summary-final(102907). pdf
18. Granada JF, Inami S, Aboodi MS, Tellez A, Milewski K, Wallace-Bradley D, Parker S, Rowland S, Nakazawa G, Vorpahl M, Kolodgie FD, Kaluza GL, Leon MB, Virmani R. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv. 2010;3:257-66.
19. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224-30.
20. Rapamune prescribing information, LAB-0579-1. 0, Wyeth Pharmaceuticals, Inc. , Philadelphia, PA 19101, December, 2012. http://labeling. pfizer. com/showlabeling. aspx?id=139
21. Cassese S, De Luca G, Ribichini F, Cernigliaro C, Sansa M, Versaci F, Proietti I, Stankovic G, Stojkovic S, Fernandez-Pereira C, Tomai F, Vassanelli C, Antoniucci D, Serruys PW, Kastrati A, Rodriguez AE. ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: a patient-level metaanalysis of randomized trials. Atherosclerosis. 2014;237:410-7.